| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Androgen | 19 | 2020 | 922 | 2.860 |
Why?
|
| Phosphoric Monoester Hydrolases | 6 | 2021 | 265 | 2.050 |
Why?
|
| Receptors, Peptide | 12 | 2024 | 88 | 1.910 |
Why?
|
| Receptors, G-Protein-Coupled | 14 | 2024 | 487 | 1.680 |
Why?
|
| Relaxin | 8 | 2024 | 22 | 1.640 |
Why?
|
| Prostatic Neoplasms | 19 | 2020 | 5990 | 1.480 |
Why?
|
| Androgens | 8 | 2016 | 558 | 0.920 |
Why?
|
| Phosphatidylinositols | 1 | 2022 | 69 | 0.840 |
Why?
|
| Infertility | 1 | 2022 | 107 | 0.760 |
Why?
|
| Glycoside Hydrolase Inhibitors | 1 | 2020 | 4 | 0.720 |
Why?
|
| Glycoside Hydrolases | 1 | 2020 | 42 | 0.700 |
Why?
|
| Nuclear Receptor Co-Repressor 1 | 3 | 2016 | 70 | 0.600 |
Why?
|
| Protein Kinase C | 2 | 2018 | 419 | 0.560 |
Why?
|
| Nuclear Receptor Coactivator 2 | 2 | 2008 | 221 | 0.520 |
Why?
|
| Metabolism | 1 | 2015 | 50 | 0.510 |
Why?
|
| Signal Transduction | 10 | 2021 | 12206 | 0.500 |
Why?
|
| Neoplasms, Hormone-Dependent | 2 | 2006 | 354 | 0.490 |
Why?
|
| Prostate | 2 | 2018 | 1139 | 0.460 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2020 | 2093 | 0.460 |
Why?
|
| Reproduction | 1 | 2015 | 277 | 0.440 |
Why?
|
| Cell Line, Tumor | 16 | 2020 | 14864 | 0.430 |
Why?
|
| Transcription, Genetic | 4 | 2018 | 3416 | 0.420 |
Why?
|
| Histone Acetyltransferases | 3 | 2009 | 441 | 0.390 |
Why?
|
| Testis | 4 | 2022 | 753 | 0.380 |
Why?
|
| Receptors, Progesterone | 3 | 2013 | 1645 | 0.370 |
Why?
|
| Cell Proliferation | 13 | 2020 | 7294 | 0.370 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2020 | 9078 | 0.360 |
Why?
|
| Animals | 32 | 2024 | 62771 | 0.360 |
Why?
|
| Testosterone | 2 | 2015 | 733 | 0.360 |
Why?
|
| HEK293 Cells | 6 | 2024 | 1473 | 0.360 |
Why?
|
| Gene Expression | 3 | 2016 | 3681 | 0.340 |
Why?
|
| DNA-Binding Proteins | 4 | 2018 | 5042 | 0.340 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2013 | 557 | 0.340 |
Why?
|
| Spermatogenesis | 2 | 2022 | 334 | 0.330 |
Why?
|
| Disease Progression | 7 | 2016 | 6893 | 0.320 |
Why?
|
| Male | 31 | 2024 | 128453 | 0.310 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2008 | 279 | 0.300 |
Why?
|
| Mice | 20 | 2024 | 35992 | 0.300 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2008 | 300 | 0.290 |
Why?
|
| Gene Expression Regulation | 2 | 2018 | 4182 | 0.290 |
Why?
|
| Transcription Factors | 6 | 2009 | 5494 | 0.290 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2011 | 1119 | 0.280 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2020 | 1725 | 0.260 |
Why?
|
| Transcriptional Activation | 2 | 2012 | 1147 | 0.260 |
Why?
|
| Cricetulus | 1 | 2024 | 215 | 0.230 |
Why?
|
| Protein Engineering | 1 | 2024 | 99 | 0.230 |
Why?
|
| CHO Cells | 1 | 2024 | 323 | 0.230 |
Why?
|
| Small Molecule Libraries | 3 | 2018 | 188 | 0.220 |
Why?
|
| Inositol Phosphates | 1 | 2022 | 27 | 0.210 |
Why?
|
| Receptor, ErbB-2 | 1 | 2013 | 2648 | 0.210 |
Why?
|
| Metribolone | 4 | 2006 | 52 | 0.210 |
Why?
|
| Nuclear Receptor Coactivator 1 | 3 | 2009 | 271 | 0.200 |
Why?
|
| Semen | 1 | 2022 | 89 | 0.200 |
Why?
|
| Mice, Transgenic | 7 | 2019 | 4371 | 0.200 |
Why?
|
| Transfection | 7 | 2013 | 3172 | 0.200 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2003 | 374 | 0.200 |
Why?
|
| Humans | 43 | 2024 | 270946 | 0.190 |
Why?
|
| Thymidine Kinase | 6 | 1999 | 224 | 0.190 |
Why?
|
| Protective Agents | 1 | 2021 | 51 | 0.180 |
Why?
|
| Anilides | 3 | 2016 | 295 | 0.180 |
Why?
|
| Androgen Receptor Antagonists | 3 | 2012 | 112 | 0.180 |
Why?
|
| Androgen Antagonists | 3 | 2016 | 434 | 0.180 |
Why?
|
| Carbon Tetrachloride Poisoning | 1 | 2019 | 13 | 0.170 |
Why?
|
| Nitriles | 4 | 2016 | 943 | 0.170 |
Why?
|
| Tosyl Compounds | 3 | 2016 | 38 | 0.170 |
Why?
|
| Germ-Line Mutation | 1 | 2004 | 1069 | 0.160 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2020 | 1014 | 0.160 |
Why?
|
| Hepatic Stellate Cells | 1 | 2018 | 30 | 0.160 |
Why?
|
| Ovarian Neoplasms | 8 | 2004 | 4774 | 0.160 |
Why?
|
| RNA, Small Interfering | 4 | 2014 | 2214 | 0.160 |
Why?
|
| Transcriptome | 2 | 2018 | 1934 | 0.150 |
Why?
|
| Cell Growth Processes | 2 | 2011 | 339 | 0.150 |
Why?
|
| Spermatozoa | 1 | 2020 | 324 | 0.150 |
Why?
|
| COS Cells | 4 | 2012 | 422 | 0.150 |
Why?
|
| Metabolic Syndrome | 1 | 2021 | 374 | 0.140 |
Why?
|
| Promoter Regions, Genetic | 5 | 2008 | 3245 | 0.140 |
Why?
|
| Repressor Proteins | 2 | 2009 | 1726 | 0.140 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2018 | 512 | 0.140 |
Why?
|
| Drug Synergism | 1 | 2020 | 1369 | 0.140 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 2399 | 0.140 |
Why?
|
| Mice, Inbred C57BL | 3 | 2024 | 7216 | 0.130 |
Why?
|
| Adenoviridae | 6 | 1999 | 1510 | 0.130 |
Why?
|
| Genetic Therapy | 6 | 1999 | 1732 | 0.130 |
Why?
|
| Binding Sites | 4 | 2012 | 2307 | 0.130 |
Why?
|
| Maleimides | 1 | 2014 | 23 | 0.120 |
Why?
|
| Cyclic AMP | 2 | 2013 | 404 | 0.120 |
Why?
|
| Liver Cirrhosis | 2 | 2019 | 1022 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2011 | 10349 | 0.120 |
Why?
|
| Gene Silencing | 2 | 2016 | 834 | 0.120 |
Why?
|
| High Mobility Group Proteins | 2 | 2007 | 65 | 0.120 |
Why?
|
| Introns | 2 | 2006 | 460 | 0.120 |
Why?
|
| p21-Activated Kinases | 1 | 2014 | 131 | 0.120 |
Why?
|
| Protein Binding | 2 | 2018 | 3536 | 0.110 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2014 | 203 | 0.110 |
Why?
|
| Receptors, Calcitriol | 2 | 2005 | 150 | 0.110 |
Why?
|
| RNA Interference | 2 | 2016 | 1398 | 0.110 |
Why?
|
| Neoplasm Metastasis | 2 | 2016 | 5324 | 0.110 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 1084 | 0.110 |
Why?
|
| HeLa Cells | 3 | 2006 | 1719 | 0.110 |
Why?
|
| Receptor, ErbB-3 | 1 | 2013 | 126 | 0.100 |
Why?
|
| Benzamides | 1 | 2018 | 1883 | 0.100 |
Why?
|
| Protein Structure, Tertiary | 4 | 2016 | 1502 | 0.100 |
Why?
|
| Cell Movement | 4 | 2014 | 2500 | 0.100 |
Why?
|
| Cyclooxygenase 2 | 1 | 2014 | 496 | 0.100 |
Why?
|
| Gene Knockout Techniques | 1 | 2013 | 272 | 0.100 |
Why?
|
| Mice, Knockout | 2 | 2020 | 5837 | 0.100 |
Why?
|
| Interleukin-8 | 1 | 2014 | 531 | 0.100 |
Why?
|
| Nuclear Receptor Coactivators | 1 | 2012 | 87 | 0.100 |
Why?
|
| Chromatin | 1 | 2018 | 1050 | 0.100 |
Why?
|
| DNA Repair | 1 | 2020 | 1886 | 0.100 |
Why?
|
| Organ Specificity | 1 | 2013 | 751 | 0.100 |
Why?
|
| Computational Biology | 1 | 2018 | 1263 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2004 | 5438 | 0.100 |
Why?
|
| High-Throughput Screening Assays | 1 | 2012 | 207 | 0.090 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 504 | 0.090 |
Why?
|
| Disease Models, Animal | 2 | 2016 | 7461 | 0.090 |
Why?
|
| Software | 1 | 2018 | 1361 | 0.090 |
Why?
|
| Mice, SCID | 1 | 2014 | 1855 | 0.090 |
Why?
|
| Models, Biological | 2 | 2011 | 3226 | 0.090 |
Why?
|
| Rats | 3 | 2016 | 6637 | 0.090 |
Why?
|
| Oncogenes | 1 | 2013 | 700 | 0.090 |
Why?
|
| Cyproterone Acetate | 1 | 2009 | 7 | 0.080 |
Why?
|
| Mammary Glands, Animal | 1 | 2013 | 635 | 0.080 |
Why?
|
| Indoles | 1 | 2014 | 1035 | 0.080 |
Why?
|
| Diet, High-Fat | 2 | 2021 | 254 | 0.080 |
Why?
|
| Butadienes | 1 | 2008 | 36 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 2335 | 0.080 |
Why?
|
| Estrogen Receptor alpha | 1 | 2013 | 744 | 0.080 |
Why?
|
| Nuclear Receptor Co-Repressor 2 | 2 | 2009 | 48 | 0.080 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2020 | 1526 | 0.080 |
Why?
|
| Substrate Specificity | 1 | 2009 | 582 | 0.080 |
Why?
|
| Leiomyoma | 1 | 2009 | 161 | 0.070 |
Why?
|
| Protein Stability | 1 | 2008 | 374 | 0.070 |
Why?
|
| Histones | 2 | 2020 | 1510 | 0.070 |
Why?
|
| Acetylation | 1 | 2008 | 519 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 2012 | 1329 | 0.070 |
Why?
|
| RNA, Untranslated | 1 | 2009 | 242 | 0.070 |
Why?
|
| Ganciclovir | 2 | 1998 | 194 | 0.070 |
Why?
|
| Thymidine | 1 | 2006 | 168 | 0.070 |
Why?
|
| Alleles | 1 | 2013 | 2508 | 0.070 |
Why?
|
| Nuclear Receptor Coactivator 3 | 1 | 2009 | 385 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 4067 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2014 | 4956 | 0.070 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2008 | 503 | 0.070 |
Why?
|
| Female | 16 | 2015 | 148508 | 0.070 |
Why?
|
| RNA, Neoplasm | 1 | 2008 | 811 | 0.070 |
Why?
|
| Cytomegalovirus | 2 | 1999 | 493 | 0.060 |
Why?
|
| Apoptosis | 4 | 2020 | 7847 | 0.060 |
Why?
|
| Osmolar Concentration | 1 | 2004 | 211 | 0.060 |
Why?
|
| Neoplasms | 1 | 2011 | 15849 | 0.060 |
Why?
|
| Binding, Competitive | 1 | 2004 | 339 | 0.060 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2005 | 257 | 0.060 |
Why?
|
| Immunohistochemistry | 4 | 2010 | 7813 | 0.060 |
Why?
|
| Ganglia, Spinal | 1 | 2005 | 251 | 0.060 |
Why?
|
| MAP Kinase Signaling System | 1 | 2008 | 887 | 0.060 |
Why?
|
| DAX-1 Orphan Nuclear Receptor | 1 | 2003 | 9 | 0.060 |
Why?
|
| Base Sequence | 2 | 2008 | 5496 | 0.060 |
Why?
|
| Testosterone Congeners | 1 | 2003 | 24 | 0.060 |
Why?
|
| Hormones | 1 | 2004 | 293 | 0.060 |
Why?
|
| Receptors, Interferon | 1 | 2003 | 43 | 0.060 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2003 | 71 | 0.050 |
Why?
|
| DNA Transposable Elements | 1 | 2004 | 252 | 0.050 |
Why?
|
| Cell Nucleus | 2 | 2006 | 1742 | 0.050 |
Why?
|
| RNA, Long Noncoding | 1 | 2009 | 618 | 0.050 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2006 | 329 | 0.050 |
Why?
|
| Hormone Antagonists | 1 | 2003 | 122 | 0.050 |
Why?
|
| Mifepristone | 1 | 2003 | 196 | 0.050 |
Why?
|
| Exons | 1 | 2006 | 1379 | 0.050 |
Why?
|
| Avian Sarcoma Viruses | 2 | 1999 | 49 | 0.050 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2022 | 123 | 0.050 |
Why?
|
| Prostatic Hyperplasia | 1 | 2003 | 223 | 0.050 |
Why?
|
| Insulin | 2 | 2022 | 1510 | 0.050 |
Why?
|
| Cytokines | 2 | 2020 | 2836 | 0.050 |
Why?
|
| Receptors, LH | 1 | 2020 | 15 | 0.050 |
Why?
|
| Hydroxamic Acids | 1 | 2003 | 459 | 0.040 |
Why?
|
| Disorders of Sex Development | 1 | 2000 | 90 | 0.040 |
Why?
|
| Adenocarcinoma | 2 | 2010 | 7936 | 0.040 |
Why?
|
| Sperm Count | 1 | 2020 | 103 | 0.040 |
Why?
|
| Antiviral Agents | 2 | 1998 | 1255 | 0.040 |
Why?
|
| Molecular Sequence Data | 3 | 2016 | 6789 | 0.040 |
Why?
|
| Mice, Nude | 5 | 2010 | 4360 | 0.040 |
Why?
|
| Meiosis | 1 | 2020 | 185 | 0.040 |
Why?
|
| Cell Line, Transformed | 1 | 2019 | 431 | 0.040 |
Why?
|
| Drug Stability | 2 | 2013 | 109 | 0.040 |
Why?
|
| Membrane Proteins | 2 | 2007 | 2953 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2008 | 6483 | 0.040 |
Why?
|
| Amino Acid Sequence | 2 | 2016 | 4644 | 0.040 |
Why?
|
| Acyclovir | 1 | 1998 | 80 | 0.040 |
Why?
|
| Cell Line | 2 | 2018 | 5437 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 6 | 2005 | 5834 | 0.040 |
Why?
|
| Topotecan | 1 | 1998 | 248 | 0.040 |
Why?
|
| Models, Molecular | 2 | 2018 | 1758 | 0.040 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1998 | 472 | 0.040 |
Why?
|
| Organoids | 1 | 2019 | 316 | 0.030 |
Why?
|
| Structure-Activity Relationship | 2 | 2013 | 1011 | 0.030 |
Why?
|
| Endometrial Neoplasms | 1 | 2006 | 1380 | 0.030 |
Why?
|
| Nuclear Proteins | 2 | 2009 | 3459 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2005 | 2618 | 0.030 |
Why?
|
| Molecular Weight | 1 | 2016 | 723 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 537 | 0.030 |
Why?
|
| Leukocytes | 1 | 1998 | 424 | 0.030 |
Why?
|
| Macaca | 1 | 2016 | 93 | 0.030 |
Why?
|
| Protein Structure, Secondary | 1 | 2016 | 342 | 0.030 |
Why?
|
| Telomere | 1 | 1998 | 534 | 0.030 |
Why?
|
| Mutation | 2 | 2006 | 15854 | 0.030 |
Why?
|
| SOX9 Transcription Factor | 2 | 2007 | 178 | 0.030 |
Why?
|
| Transplantation, Heterologous | 2 | 2010 | 1089 | 0.030 |
Why?
|
| Hydrogen Bonding | 1 | 2013 | 138 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2013 | 165 | 0.030 |
Why?
|
| Electric Impedance | 1 | 2013 | 101 | 0.030 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 1997 | 523 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 3655 | 0.020 |
Why?
|
| Swine | 1 | 2016 | 1610 | 0.020 |
Why?
|
| Blotting, Western | 2 | 2009 | 3648 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2013 | 640 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2003 | 3657 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2006 | 5108 | 0.020 |
Why?
|
| Up-Regulation | 2 | 2007 | 2465 | 0.020 |
Why?
|
| Desmin | 1 | 2009 | 64 | 0.020 |
Why?
|
| Smad2 Protein | 1 | 2009 | 91 | 0.020 |
Why?
|
| Random Allocation | 1 | 2010 | 747 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2010 | 759 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2012 | 1037 | 0.020 |
Why?
|
| Caveolin 1 | 1 | 2009 | 204 | 0.020 |
Why?
|
| Leydig Cells | 1 | 2007 | 43 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2010 | 2314 | 0.020 |
Why?
|
| Breast Neoplasms | 2 | 2003 | 16186 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2013 | 1603 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2009 | 1046 | 0.020 |
Why?
|
| Calcium Channel Agonists | 1 | 2005 | 15 | 0.020 |
Why?
|
| Integrases | 1 | 2007 | 266 | 0.020 |
Why?
|
| Survival Analysis | 3 | 2007 | 9307 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2006 | 320 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 2109 | 0.020 |
Why?
|
| Calcitriol | 1 | 2005 | 146 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2005 | 451 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2006 | 261 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2006 | 351 | 0.010 |
Why?
|
| Antibodies | 1 | 2007 | 835 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2005 | 586 | 0.010 |
Why?
|
| Ligands | 1 | 2006 | 1061 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2006 | 783 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 2005 | 685 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2009 | 1132 | 0.010 |
Why?
|
| Neoplasm Transplantation | 2 | 1997 | 1567 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2005 | 1153 | 0.010 |
Why?
|
| Dihydrotestosterone | 1 | 2002 | 116 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2005 | 704 | 0.010 |
Why?
|
| Adult | 3 | 2022 | 81555 | 0.010 |
Why?
|
| Threonine | 1 | 2002 | 165 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2010 | 5782 | 0.010 |
Why?
|
| Alanine | 1 | 2002 | 251 | 0.010 |
Why?
|
| Genetic Vectors | 2 | 1999 | 1884 | 0.010 |
Why?
|
| Cell Survival | 2 | 1998 | 3081 | 0.010 |
Why?
|
| Biological Transport | 1 | 2002 | 647 | 0.010 |
Why?
|
| Heat-Shock Proteins | 1 | 2002 | 340 | 0.010 |
Why?
|
| Cell Division | 1 | 2005 | 2716 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2009 | 4985 | 0.010 |
Why?
|
| Mutagenesis, Insertional | 1 | 2000 | 218 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 2000 | 351 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2002 | 1280 | 0.010 |
Why?
|
| Proteins | 1 | 2007 | 2047 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2000 | 1062 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 5161 | 0.010 |
Why?
|
| DNA Primers | 1 | 2000 | 1508 | 0.010 |
Why?
|
| Simplexvirus | 1 | 1999 | 181 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2000 | 909 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2000 | 1586 | 0.010 |
Why?
|
| Pedigree | 1 | 2000 | 1983 | 0.010 |
Why?
|
| Reference Values | 1 | 1998 | 1153 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 1998 | 14679 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2000 | 2314 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1998 | 3542 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 1998 | 1985 | 0.010 |
Why?
|
| DNA | 1 | 1998 | 3074 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2010 | 33827 | 0.010 |
Why?
|
| Phenotype | 1 | 2000 | 6465 | 0.010 |
Why?
|
| Age Factors | 1 | 1998 | 5496 | 0.000 |
Why?
|
| Prognosis | 1 | 2006 | 22458 | 0.000 |
Why?
|
| Middle Aged | 2 | 2009 | 90020 | 0.000 |
Why?
|
| Combined Modality Therapy | 1 | 1998 | 9043 | 0.000 |
Why?
|
| Aged | 1 | 1998 | 73160 | 0.000 |
Why?
|